Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for patients with serious diseases, particularly cancer and other unmet medical needs. The company leverages its expertise in molecular biology and drug development to create targeted treatments that aim to improve patient outcomes. With a strong emphasis on research and clinical trials, Incyte strives to advance its pipeline of potential medications, which includes both its proprietary compounds and collaborations with other pharmaceutical partners. Through its commitment to scientific excellence and patient-centric approaches, Incyte aims to address significant healthcare challenges and enhance the quality of life for individuals suffering from complex conditions. Read More
Incyte (Nasdaq:INCY) announced today equity inducement awards grants to David H. Gardner, the Company’s new Executive Vice President, Chief Strategy Officer, pursuant to the Company’s 2024 Inducement Stock Incentive Plan. The awards were approved by the compensation committee of the Company’s Board of Directors as an inducement material to the new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
STRATA Skin Sciences Inc. (NASDAQ: SSKN) witnessed a dramatic surge in its stock price today, climbing 51.18% following the publication of a groundbreaking peer-reviewed study. The research highlights the superior efficacy and safety of its 308nm Excimer laser, specifically the XTRAC® system, when combined with Janus Kinase (JAK) inhibitors
In a recent episode of "Mad Money," Jim Cramer identified several stocks in the S&P 500 that he believes are undervalued, offering growth potential despite the market's record highs.
Incyte (Nasdaq:INCY) announces that Dave Gardner has been appointed Executive Vice President and Chief Strategy Officer (CSO) effective today, September 22, 2025. In his new role, Mr. Gardner will serve as a key member of the Executive Leadership Team and be responsible for the Company’s strategy and business development.
Incyte (Nasdaq: INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Opzelura® (ruxolitinib) cream 1.5%, a topical Janus kinase (JAK) inhibitor, for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised children two years of age and older whose disease is not well controlled with topical prescription therapies, or when those therapies are not recommended.
Incyte (Nasdaq:INCY) today announced new 24-week interim data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). These data will support the planned regulatory submissions for povorcitinib in HS in Europe and the United States in 2025 and early 2026, respectively.
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability.
But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Curious about the top performers within the S&P500 index one hour before the close of the markets on Friday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Wall Street has issued downbeat forecasts for the stocks in this article.
These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.
Today Incyte (Nasdaq:INCY) announced that it will present new data from its dermatology portfolio at the European Association of Dermatology and Venerology (EADV) 2025 Congress, held from September 17 – 20, in Paris. Highlights include late-breaking, oral and poster presentations featuring data for povorcitinib (INCB054707), an oral small-molecule JAK1 inhibitor, and ruxolitinib cream (Opzelura®), a topical JAK1/2 inhibitor.
Incyte (Nasdaq:INCY) announced the launch of HS TRUTHS, a new educational campaign aimed at revealing the authentic and often hidden realities of living with hidradenitis suppurativa (HS), a chronic inflammatory skin condition. This initiative moves beyond superficial awareness by sharing the physical pain, emotional burden and years-long diagnostic delays that many people living with HS endure. Through unfiltered, patient-led storytelling, HS TRUTHS encourages deeper understanding among healthcare professionals and supports stronger communication between patients and providers.
Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY)
jumped 2.4% in the afternoon session after Barclays initiated coverage on the stock with an Overweight rating, helping the shares reach a new 52-week high. The investment bank noted a "compelling inflection point" for the biotechnology firm, highlighting multiple maturing assets that could drive future revenue growth. Further bolstering investor confidence, RBC Capital raised its price target on Incyte to $72, citing strong demand-driven growth from its products. The stock's climb to a 52-week high of $87.27 reflects significant positive momentum, building on a 22.5% year-to-date return. The move was also supported by broader strength in the biotechnology sector and a positive technical trend, with the stock trading above its key 50-day and 200-day moving averages.
While profitability is essential, it doesn’t guarantee long-term success.
Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
Analysts expect nearly 450% EPS growth in 2025, making execution on its core portfolio critical for sustaining the outperformance experienced so far YTD.
Discover Incyte Corp (INCY), an undervalued biotech stock with strong profitability, solid financial health, and promising growth potential for value investors.
Incyte (Nasdaq: INCY) announced today equity inducement awards grants to Soni Basi, the Company’s new Executive Vice President and Chief Human Resources Officer, pursuant to the Company’s 2024 Inducement Stock Incentive Plan. The awards were approved by the compensation committee of the Company’s Board of Directors as an inducement material to the new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
Incyte (Nasdaq:INCY) announces that Soni Basi has been appointed Executive Vice President and Chief Human Resources Officer (CHRO) effective today, August 25, 2025. In her new role, Ms. Basi will serve as a key member of the Executive Leadership Team and be responsible for shaping the Company’s global human resources strategy including talent acquisition, organizational design and professional development.
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets.
But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.
The stocks in this article are all trading near their 52-week highs.
This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.
